AN2 Therapeutics Inc (ANTX)
2.47
+0.08
(+3.35%)
USD |
NASDAQ |
May 02, 11:58
AN2 Therapeutics Enterprise Value: -36.00M for May 1, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 01, 2024 | -36.00M |
| April 30, 2024 | -35.71M |
| April 29, 2024 | -36.60M |
| April 26, 2024 | -38.09M |
| April 25, 2024 | -39.28M |
| April 24, 2024 | -35.71M |
| April 23, 2024 | -36.60M |
| April 22, 2024 | -37.04M |
| April 19, 2024 | -33.76M |
| April 18, 2024 | -36.44M |
| April 17, 2024 | -33.46M |
| April 16, 2024 | -33.76M |
| April 15, 2024 | -32.87M |
| April 12, 2024 | -25.72M |
| April 11, 2024 | -17.98M |
| April 10, 2024 | -16.79M |
| April 09, 2024 | -16.50M |
| April 08, 2024 | -17.69M |
| April 05, 2024 | -17.69M |
| April 04, 2024 | -10.54M |
| April 03, 2024 | -6.969M |
| April 02, 2024 | -6.076M |
| April 01, 2024 | 4.642M |
| March 28, 2024 | -10.54M |
| March 27, 2024 | -11.43M |
| Date | Value |
|---|---|
| March 26, 2024 | -14.41M |
| March 25, 2024 | -11.73M |
| March 22, 2024 | -8.160M |
| March 21, 2024 | -8.755M |
| March 20, 2024 | -11.73M |
| March 19, 2024 | -15.90M |
| March 18, 2024 | -19.47M |
| March 15, 2024 | -17.98M |
| March 14, 2024 | -16.88M |
| March 13, 2024 | -18.67M |
| March 12, 2024 | -21.04M |
| March 11, 2024 | -19.56M |
| March 08, 2024 | -20.15M |
| March 07, 2024 | -19.86M |
| March 06, 2024 | -21.94M |
| March 05, 2024 | -23.42M |
| March 04, 2024 | -24.61M |
| March 01, 2024 | -18.07M |
| February 29, 2024 | -18.67M |
| February 28, 2024 | -17.48M |
| February 27, 2024 | -18.67M |
| February 26, 2024 | -14.20M |
| February 23, 2024 | -15.39M |
| February 22, 2024 | -8.851M |
| February 21, 2024 | -8.256M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-39.28M
Minimum
Apr 25 2024
533.04M
Maximum
Jan 09 2024
164.19M
Average
103.99M
Median
Enterprise Value Benchmarks
| Gilead Sciences Inc | 76.97B |
| QuidelOrtho Corp | 4.898B |
| CymaBay Therapeutics Inc (DELISTED) | 3.443B |
| Insmed Inc | 4.172B |
| Revance Therapeutics Inc | 570.15M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -16.90M |
| Total Expenses (Quarterly) | 18.82M |
| EPS Diluted (Quarterly) | -0.57 |
| Earnings Yield | -114.2% |